BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun 2017;8:1679. [PMID: 29162833 DOI: 10.1038/s41467-017-01834-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Wang H, Li G, Liu M, Ding J, Huang X, Gao W, Huayue W. A photocleavable low molecular weight hydrogel for light-triggered drug delivery. Chinese Chemical Letters 2019;30:485-8. [DOI: 10.1016/j.cclet.2018.06.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
2 Jin T, Wang P, Long X, Jiang K, Song P, Wu W, Xu G, Zhou Y, Li J, Liu T. Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia. ChemMedChem 2021;16:1477-87. [PMID: 33591599 DOI: 10.1002/cmdc.202000882] [Reference Citation Analysis]
3 Lei H, Yang L, Zhou L, Tong Y, Wu Y. Targeting acute myeloid leukemia CD34+ stem/progenitor cells with small molecule inhibitor MK-8776. Leuk Res 2018;72:71-3. [PMID: 30103203 DOI: 10.1016/j.leukres.2018.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Yu X, Li W, Liu H, Deng Q, Wang X, Hu H, Xu-Monette ZY, Xiong W, Lu Z, Young KH, Wang W, Li Y. Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol 2020;13:40. [PMID: 32357935 DOI: 10.1186/s13045-020-00869-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Schuler F, Afreen S, Manzl C, Häcker G, Erlacher M, Villunger A. Checkpoint kinase 1 is essential for fetal and adult hematopoiesis. EMBO Rep 2019;20:e47026. [PMID: 31379128 DOI: 10.15252/embr.201847026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Trojani A, Di Camillo B, Bossi LE, Leuzzi L, Greco A, Tedeschi A, Frustaci AM, Deodato M, Zamprogna G, Beghini A, Cairoli R. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells. Cancers (Basel) 2021;13:1837. [PMID: 33921415 DOI: 10.3390/cancers13081837] [Reference Citation Analysis]
7 Chamoun K, Borthakur G. Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia. Expert Opin Investig Drugs 2018;27:661-6. [PMID: 30084282 DOI: 10.1080/13543784.2018.1508448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. Mol Cancer Res 2020;18:91-104. [PMID: 31649026 DOI: 10.1158/1541-7786.MCR-19-0585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
9 Recasens A, Munoz L. Targeting Cancer Cell Dormancy. Trends Pharmacol Sci 2019;40:128-41. [PMID: 30612715 DOI: 10.1016/j.tips.2018.12.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 24.0] [Reference Citation Analysis]
10 Wu L, Chatla S, Lin Q, Chowdhury FA, Geldenhuys W, Du W. Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia. Nat Commun 2021;12:6936. [PMID: 34836965 DOI: 10.1038/s41467-021-27300-w] [Reference Citation Analysis]
11 Damen MPF, van Rheenen J, Scheele CLGJ. Targeting dormant tumor cells to prevent cancer recurrence. FEBS J 2020. [PMID: 33190412 DOI: 10.1111/febs.15626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 2020;12:E3511. [PMID: 33255818 DOI: 10.3390/cancers12123511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Aguiñiga-Sánchez I, Meléndez-Ibarra FM, Ledesma-Martínez E, Weiss-Steider B, Fajardo-Orduña GR, Rangel-Corona R, García-Gervasio SN, Ramírez-Padilla MG, Lara-Castañeda JL, Santiago-Osorio E. Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity. J Oncol 2021;2021:6635650. [PMID: 33727925 DOI: 10.1155/2021/6635650] [Reference Citation Analysis]
14 Hu W, Wang Z, Zhang H, Mahaman YAR, Huang F, Meng D, Zhou Y, Wang S, Jiang N, Xiong J, Westermarck J, Lu Y, Wang J, Wang X, Shentu Y, Liu R. Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling. Neurotherapeutics. [DOI: 10.1007/s13311-022-01204-z] [Reference Citation Analysis]
15 Li N, Wang B. Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-00932-7] [Reference Citation Analysis]
16 Jin J, Mao S, Li F, Li X, Huang X, Yu M, Guo W, Jin J. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells. Med Oncol 2019;36:77. [PMID: 31372848 DOI: 10.1007/s12032-019-1302-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li M, Huang T, Li X, Shi Z, Sheng Y, Hu M, Song K. GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2+ Macrophage Infiltration in Mice. Onco Targets Ther 2021;14:2661-72. [PMID: 33897258 DOI: 10.2147/OTT.S297132] [Reference Citation Analysis]
18 Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol 2018;29:1304-11. [PMID: 29788155 DOI: 10.1093/annonc/mdy076] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]